February 2023 in “Lasers in Medical Science” 
1 citations
,
December 2022 in “Journal of cosmetic dermatology” This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.
1 citations
,
December 2022 in “JAMA Dermatology” This study found that the HairComb algorithm achieved high accuracy in quantifying percentage hair loss across various types of alopecia, suggesting its potential for standardized automated assessments.
8 citations
,
October 2022 in “Dermatologic Therapy” In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.
13 citations
,
September 2022 in “Journal of Drugs in Dermatology” This study suggests that antihistamines show promise as adjunct treatments for alopecia areata, but the role of dupilumab needs further investigation due to mixed results regarding hair regrowth and adverse effects.
September 2022 in “International Journal of Trichology” In this study, microneedling and intralesional corticosteroid injections in patients with alopecia areata showed similar hair regrowth effectiveness, with microneedling resulting in more uniform but less dense regrowth and fewer side effects.
August 2022 in “International Journal of Dermatology” In this study, low-dose oral minoxidil and sublingual minoxidil were generally well-tolerated in children with alopecia, with mild hypertrichosis as the most common adverse event.
15 citations
,
July 2022 in “Biomedicines” This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.
11 citations
,
June 2022 in “Frontiers in immunology” This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.
1 citations
,
May 2022 in “International Journal of Trichology” This article discusses hair loss conditions and available camouflage options after medical and surgical interventions fail, but it reports no new clinical findings.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
2 citations
,
March 2022 in “Dermatologic Therapy” This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.
7 citations
,
February 2022 in “Journal of Cosmetic Dermatology” In this randomized controlled trial, intralesional vitamin D3 injections significantly improved localized alopecia areata symptoms compared to a saline placebo, with minimal and transient side effects, suggesting vitamin D3 as an effective treatment option without needing prior serum vitamin D level measurement.
37 citations
,
December 2021 in “Cells” This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.
13 citations
,
November 2021 in “Pediatric Dermatology” This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.
10 citations
,
November 2021 in “PLoS ONE” This study suggests that the T allele of the SNP rs2476601 in the PTPN22 gene may increase the risk of alopecia areata, although further studies are necessary to validate this finding across different populations.
15 citations
,
September 2021 in “Journal of Clinical Medicine” This study observed that in children who unintentionally consumed high-dose oral minoxidil, 65% developed hypertrichosis, predominantly on the face, and 15% experienced mild systemic side effects.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
1 citations
,
June 2021 in “Journal of Cosmetic Dermatology” In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.
24 citations
,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” This review highlights current knowledge about quality of life assessment in alopecia areata, noting limited use of existing instruments and a need for further validation.
9 citations
,
May 2021 in “International Journal of Dermatology” In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.
23 citations
,
February 2021 in “Dermatologic therapy” This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.
2 citations
,
January 2021 in “Indian Journal of Dermatology, Venereology and Leprology” This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.
19 citations
,
January 2021 in “Journal of the American Academy of Dermatology” This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.
6 citations
,
November 2020 in “Clinical Cosmetic and Investigational Dermatology” This study found that intralesional injections of triamcinolone acetonide at 5 mg/mL are as effective and safe as 10 mg/mL for treating patchy alopecia areata on the scalp, with similar hair regrowth rates, side effects, and recurrence observed between the two dosages.
26 citations
,
October 2020 in “Pediatric Dermatology” This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.
56 citations
,
August 2020 in “American Journal of Clinical Dermatology” This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.
14 citations
,
August 2020 in “Dermatologic Therapy” This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.
3 citations
,
June 2020 in “Journal of Dermatological Treatment” In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.
19 citations
,
June 2020 in “International Journal of Dermatology” In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.
13 citations
,
April 2020 in “Dermatology and therapy” This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.
86 citations
,
January 2020 in “British Journal of Dermatology” This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.
19 citations
,
July 2019 in “Journal of Cosmetic Dermatology” This study found that in patients with patchy alopecia areata, certain trichoscopic features like upright regrowing hairs and pigtail hairs are positive predictive markers for treatment success.
10 citations
,
July 2019 in “Indian Journal of Dermatology” This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.
9 citations
,
June 2019 in “Archives of Dermatological Research” This study found that both topical calcipotriol and narrow band ultraviolet B phototherapy improved hair regrowth and vitamin D3 levels in alopecia areata patients.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.
9 citations
,
January 2019 in “International Journal of Trichology” In this study, combining topical calcipotriol with mometasone results in greater improvement in alopecia areata treatment compared to using mometasone alone, as evidenced by a more significant reduction in SALT score over 24 weeks.
66 citations
,
December 2018 in “Dermatology” This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.
11 citations
,
November 2018 in “Journal of the American Academy of Dermatology” This study found that among patients with alopecia areata treated with the JAK inhibitor tofacitinib, 34% achieved complete regrowth of eyebrows and 39% achieved complete regrowth of eyelashes, highlighting differences in treatment responses across hair-bearing sites.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.
49 citations
,
August 2018 in “International Journal of Dermatology” In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.
89 citations
,
August 2018 in “JAMA Dermatology” This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
17 citations
,
March 2018 in “Pediatric dermatology” This study suggests that hydroxychloroquine may benefit some children with alopecia areata, as five out of nine patients showed improvement, although side effects like gastrointestinal intolerance and headache were noted.
45 citations
,
January 2018 in “International Journal of Dermatology” This review explores nail changes associated with alopecia areata, noting their prevalence and impact on appearance and function, but reports no new clinical findings; the authors call for larger controlled trials.
21 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study suggests that statins may help treat acute alopecia areata, with animal experiments showing increased regulatory T cell populations after statin treatment in mice with the condition.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.
63 citations
,
May 2017 in “American Journal of Clinical Dermatology” This review found that patients with alopecia areata may have lower levels of vitamin D, zinc, and folate, but conflicting evidence precludes definitive clinical recommendations for micronutrient supplementation.
22 citations
,
May 2017 in “Journal of dermatological treatment” This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.
39 citations
,
January 2017 in “Dermatologic Therapy” This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.
14 citations
,
January 2017 in “Skin appendage disorders” This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.
36 citations
,
December 2016 in “Journal of The American Academy of Dermatology” In this study, researchers evaluated the hair pull test and found that normal values should be reduced to two hairs or fewer, with no significant impact from hair washing, brushing, or lifestyle factors such as hair texture and medication use.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
16 citations
,
March 2016 in “Clinical ophthalmology” In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.
50 citations
,
January 2016 in “Journal of the American Academy of Dermatology” This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.
18 citations
,
December 2015 in “PubMed” This study found that intralesional triamcinolone was more effective than topical betamethasone for hair regrowth in patients with localized alopecia areata.
38 citations
,
June 2015 in “PubMed” This study found that topical calcipotriol may safely and effectively treat mild-to-moderate patchy alopecia areata, with significant hair regrowth observed in the majority of participants over 12 weeks.
36 citations
,
January 2015 in “Dermatology” In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
49 citations
,
November 2013 in “JAMA dermatology” This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.
205 citations
,
April 2013 in “British Journal of Dermatology” In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.
20 citations
,
January 2013 in “Evidence-based complementary and alternative medicine” This study found that TGPC plus CGT was more effective than CGT alone in reducing alopecia areata severity in children over 12 months, with similar safety profiles.
18 citations
,
August 2012 in “Chinese journal of integrative medicine/Chinese Journal of Integrative Medicine” This study reported that total glucosides of paeony capsules were as effective and safe as compound glycyrrhizin tablets for treating mild to moderate alopecia areata.
21 citations
,
February 2012 in “Journal of the European Academy of Dermatology and Venereology” This study found that late-onset alopecia areata is more common in women and tends to present with milder symptoms, with some patients achieving complete hair regrowth in mild cases.
37 citations
,
November 2011 in “Photodermatology Photoimmunology & Photomedicine” This study found that narrowband UVB phototherapy alone is not very effective for severe alopecia areata, with improved responses noted primarily in patients also receiving corticosteroid injections.
100 citations
,
June 2011 in “Journal of The American Academy of Dermatology” This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.
48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
37 citations
,
January 2010 in “International Journal of Trichology” In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.
50 citations
,
December 2009 in “Journal of The European Academy of Dermatology and Venereology” This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.
23 citations
,
January 2009 in “Veterinary Dermatology” This study found that recombinant hepatitis B vaccine may increase the risk of alopecia areata onset in older predisposed mice but larger trials suggest this effect might lie within normal variation.
196 citations
,
June 2008 in “International Journal of Dermatology” This study found that dermoscopic indicators like black dots and tapering hairs are valuable markers for diagnosing and assessing the severity and activity of alopecia areata in Asian patients.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
61 citations
,
January 2007 in “Indian Journal of Dermatology Venereology and Leprology” This study found that garlic gel significantly improved the efficacy of topical betamethasone valerate in treating alopecia areata compared to placebo.
27 citations
,
January 2005 in “American Journal of Clinical Dermatology” This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.
219 citations
,
March 2004 in “Journal of The American Academy of Dermatology” In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
162 citations
,
August 2002 in “Survey of Ophthalmology” This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.
123 citations
,
February 2002 in “Journal of The American Academy of Dermatology” Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.
180 citations
,
January 2002 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that vitamin D receptor knockout mice exhibit impaired epidermal differentiation and progressive hair loss, suggesting the importance of the vitamin D receptor in normal skin and hair follicle development.
122 citations
,
November 1998 in “Archives of Dermatology” This study found that aromatherapy involving essential oils significantly improved symptoms of alopecia areata compared to carrier oils alone in a randomized controlled trial.
